Based on Clarity's multi-model valuation engine, ABBV (ABBV) has an estimated fair value of $70.48 per share, compared to its current market price of $232.35. The stock is currently trading 69.7% above Clarity's fair value estimate, resulting in a verdict of SIGNIFICANTLY OVERVALUED.

This valuation blends 3 independent models — including EV/Revenue, Comparable Companies, ROIC Fade. The primary weight is given to the EV/Revenue model, with Bayesian triangulation used to reconcile the estimates into a single blended fair value. The 3 models show moderate agreement with a 36% spread between the highest and lowest estimates.

Monte Carlo simulation across 5,000 scenarios estimates a 48.3% probability that the stock is trading below its intrinsic value, with a median simulated value of $226.01.

ABBV is classified under the Pharma / Biotech sector, and this valuation is based on 10-K · Filed 2026-02-20 filings sourced directly from SEC EDGAR. All models use trailing twelve month (TTM) financials where available, with sector-appropriate growth and discount rate assumptions.